{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T22:04:50Z","timestamp":1793138690221,"version":"4.5.0"},"reference-count":91,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrinology and Metabolism Clinics of North America"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.ecl.2021.12.004","type":"journal-article","created":{"date-parts":[[2022,5,11]],"date-time":"2022-05-11T05:16:00Z","timestamp":1652246160000},"page":"287-304","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":127,"title":["2022\u00a0Update on Clinical Management of Graves Disease and Thyroid Eye Disease"],"prefix":"10.1016","volume":"51","author":[{"given":"Thanh D.","family":"Hoang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek J.","family":"Stocker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva L.","family":"Chou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry B.","family":"Burch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"15","key":"10.1016\/j.ecl.2021.12.004_bib1","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1001\/archinte.164.15.1675","article-title":"Hyperthyroidism and risk of atrial fibrillation or flutter: a population-based study","volume":"164","author":"Frost","year":"2004","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.ecl.2021.12.004_bib2","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ejim.2019.06.012","article-title":"Increased risk of venous thromboembolism among patients with hyperthyroidism: a systematic review and meta-analysis of cohort studies","volume":"67","author":"Srisawat","year":"2019","journal-title":"Eur J Intern Med"},{"issue":"7","key":"10.1016\/j.ecl.2021.12.004_bib3","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1089\/thy.2019.0543","article-title":"Incidence and mortality of myocardial infarction and stroke in patients with hyperthyroidism: A Nationwide Cohort Study in Korea","volume":"30","author":"Kim","year":"2020","journal-title":"Thyroid"},{"issue":"1","key":"10.1016\/j.ecl.2021.12.004_bib4","first-page":"65","article-title":"Antipsychotics in hyperthyroid-related psychosis: case report and systematic review","volume":"39","author":"Golub","year":"2018","journal-title":"Neuro Endocrinol Lett"},{"issue":"7","key":"10.1016\/j.ecl.2021.12.004_bib5","doi-asserted-by":"crossref","first-page":"699","DOI":"10.4158\/EP-2019-0454","article-title":"Thyrotoxic periodic paralysis and complicated thyrotoxicosis, two presentations of hyperthyroidism with notable differences in their clinical manifestations: an experience from a Tertiary Care Hospital in the United States","volume":"26","author":"Rivas","year":"2020","journal-title":"Endocr Pract"},{"key":"10.1016\/j.ecl.2021.12.004_bib6","series-title":"Endocrine and metabolic medical emergencies: a clinician's guide","article-title":"Life-threatening thyrotoxicosis","author":"Warnock","year":"2018"},{"issue":"10","key":"10.1016\/j.ecl.2021.12.004_bib7","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1089\/thy.2016.0229","article-title":"2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis","volume":"26","author":"Ross","year":"2016","journal-title":"Thyroid"},{"issue":"1","key":"10.1016\/j.ecl.2021.12.004_bib8","doi-asserted-by":"crossref","first-page":"97","DOI":"10.4158\/EP-2019-0363","article-title":"TSH receptor antibodies: relevance & utility","volume":"26","author":"Kahaly","year":"2020","journal-title":"Endocr Pract"},{"issue":"2","key":"10.1016\/j.ecl.2021.12.004_bib9","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.ecl.2014.02.001","article-title":"Management of Graves' disease: an overview and comparison of clinical practice guidelines with actual practice trends","volume":"43","author":"Muldoon","year":"2014","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"10","key":"10.1016\/j.ecl.2021.12.004_bib10","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1089\/thy.2019.0814","article-title":"Long-Term Treatment of Hyperthyroidism with Antithyroid Drugs: 35 Years of Personal Clinical Experience","volume":"30","author":"Azizi","year":"2020","journal-title":"Thyroid"},{"issue":"5","key":"10.1016\/j.ecl.2021.12.004_bib11","doi-asserted-by":"crossref","first-page":"R261","DOI":"10.1530\/EJE-18-0678","article-title":"ANNIVERSARY REVIEW: Antithyroid drug therapy: 70 years later","volume":"179","author":"Burch","year":"2018","journal-title":"Eur J Endocrinol"},{"issue":"8","key":"10.1016\/j.ecl.2021.12.004_bib12","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1089\/thy.2016.0222","article-title":"Antithyroid Drugs-The Most Common Treatment for Graves' Disease in the United States: A Nationwide Population-Based Study","volume":"26","author":"Brito","year":"2016","journal-title":"Thyroid"},{"issue":"12","key":"10.1016\/j.ecl.2021.12.004_bib13","doi-asserted-by":"crossref","first-page":"4549","DOI":"10.1210\/jc.2012-2802","article-title":"A\u00a02011 survey of clinical practice patterns in the management of Graves' disease","volume":"97","author":"Burch","year":"2012","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.ecl.2021.12.004_bib14","first-page":"1516","article-title":"A\u00a0prospective randomized trial of antithyroid drug dose in Graves' disease therapy. European Multicenter Study Group on Antithyroid Drug Treatment","volume":"76","author":"Reinwein","year":"1993","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.ecl.2021.12.004_bib15","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1089\/thy.2014.0084","article-title":"Comparison of efficacy and adverse effects between methimazole 15\u00a0mg+inorganic iodine 38\u00a0mg\/day and methimazole 30\u00a0mg\/day as initial therapy for Graves' disease patients with moderate to severe hyperthyroidism","volume":"25","author":"Sato","year":"2015","journal-title":"Thyroid"},{"issue":"12","key":"10.1016\/j.ecl.2021.12.004_bib16","doi-asserted-by":"crossref","first-page":"4776","DOI":"10.1210\/jc.2013-2569","article-title":"Analysis of 754 cases of antithyroid drug-induced agranulocytosis over 30 years in Japan","volume":"98","author":"Nakamura","year":"2013","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.ecl.2021.12.004_bib17","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1530\/eje.1.01904","article-title":"Effect of long-term continuous methimazole treatment of hyperthyroidism: comparison with radioiodine","volume":"152","author":"Azizi","year":"2005","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"10.1016\/j.ecl.2021.12.004_bib18","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1089\/thy.2010.0181","article-title":"Outcome of very long-term treatment with antithyroid drugs in Graves' hyperthyroidism associated with Graves' orbitopathy","volume":"21","author":"Elbers","year":"2011","journal-title":"Thyroid"},{"issue":"12","key":"10.1016\/j.ecl.2021.12.004_bib19","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1089\/thy.2015.0195","article-title":"Outcomes in Relapsed Graves' Disease Patients Following Radioiodine or Prolonged Low Dose of Methimazole Treatment","volume":"25","author":"Villagelin","year":"2015","journal-title":"Thyroid"},{"issue":"9","key":"10.1016\/j.ecl.2021.12.004_bib20","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1089\/thy.2011.0039","article-title":"Sustained control of Graves' hyperthyroidism during long-term low-dose antithyroid drug therapy of patients with severe Graves' orbitopathy","volume":"21","author":"Laurberg","year":"2011","journal-title":"Thyroid"},{"issue":"5","key":"10.1016\/j.ecl.2021.12.004_bib21","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.ando.2020.05.002","article-title":"Management of thyroid dysfunctions in the elderly. French Endocrine Society consensus 2019 guidelines. Short version","volume":"81","author":"Goichot","year":"2020","journal-title":"Ann Endocrinol (Paris)"},{"issue":"3","key":"10.1016\/j.ecl.2021.12.004_bib22","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0001-2998(96)80020-1","article-title":"Radioiodine and thyroid disease: the beginning","volume":"26","author":"Becker","year":"1996","journal-title":"Semin Nucl Med"},{"issue":"1","key":"10.1016\/j.ecl.2021.12.004_bib23","first-page":"16","article-title":"Current Knowledge on Graves' Orbitopathy","volume":"10","author":"Gontarz-Nowak","year":"2020","journal-title":"J\u00a0Clin Med"},{"issue":"6","key":"10.1016\/j.ecl.2021.12.004_bib24","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1089\/thy.2010.0417","article-title":"Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists","volume":"21","author":"Bahn Chair","year":"2011","journal-title":"Thyroid"},{"issue":"2","key":"10.1016\/j.ecl.2021.12.004_bib25","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1056\/NEJM199801083380201","article-title":"Relation between therapy for hyperthyroidism and the course of Graves' ophthalmopathy","volume":"338","author":"Bartalena","year":"1998","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.ecl.2021.12.004_bib26","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1530\/EJE-07-0666","article-title":"Consensus statement of the European Group on Graves' orbitopathy (EUGOGO) on management of GO","volume":"158","author":"Bartalena","year":"2008","journal-title":"Eur J Endocrinol"},{"issue":"7","key":"10.1016\/j.ecl.2021.12.004_bib27","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1097\/RLU.0000000000003086","article-title":"Effect of Different 131I Dose Strategies for Treatment of Hyperthyroidism on Graves' Ophthalmopathy","volume":"45","author":"Ariamanesh","year":"2020","journal-title":"Clin Nucl Med"},{"issue":"2","key":"10.1016\/j.ecl.2021.12.004_bib28","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1089\/105072502753522365","article-title":"The effect of methimazole on cure rates after radioiodine treatment for Graves' hyperthyroidism: a randomized clinical trial","volume":"12","author":"Braga","year":"2002","journal-title":"Thyroid"},{"issue":"3","key":"10.1016\/j.ecl.2021.12.004_bib29","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1089\/thy.2019.0132","article-title":"Patterns of use, efficacy, and safety of treatment options for patients with Graves' Disease: A Nationwide Population-Based Study","volume":"30","author":"Brito","year":"2020","journal-title":"Thyroid"},{"issue":"4","key":"10.1016\/j.ecl.2021.12.004_bib30","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1089\/thy.2016.0343","article-title":"Comparative effectiveness of treatment choices for Graves' Hyperthyroidism: a Historical Cohort Study","volume":"27","author":"Sundaresh","year":"2017","journal-title":"Thyroid"},{"key":"10.1016\/j.ecl.2021.12.004_bib31","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s13044-020-00077-8","article-title":"Should radioiodine now be first line treatment for Graves' disease?","volume":"13","author":"Okosieme","year":"2020","journal-title":"Thyroid Res"},{"issue":"4","key":"10.1016\/j.ecl.2021.12.004_bib32","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/S2213-8587(19)30059-2","article-title":"Primary therapy of Graves' disease and cardiovascular morbidity and mortality: a linked-record cohort study","volume":"7","author":"Okosieme","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"10","key":"10.1016\/j.ecl.2021.12.004_bib33","doi-asserted-by":"crossref","first-page":"3700","DOI":"10.1210\/jc.2009-0747","article-title":"Thyroid-associated ophthalmopathy after treatment for Graves' hyperthyroidism with antithyroid drugs or iodine-131","volume":"94","author":"Tr\u00e4isk","year":"2009","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"7","key":"10.1016\/j.ecl.2021.12.004_bib34","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1089\/thy.2010.1640","article-title":"The tale of radioiodine and Graves' orbitopathy","volume":"20","author":"Ponto","year":"2010","journal-title":"Thyroid"},{"issue":"5","key":"10.1016\/j.ecl.2021.12.004_bib35","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1089\/thy.2012.0258","article-title":"Cohort study on radioactive iodine-induced hypothyroidism: implications for Graves' ophthalmopathy and optimal timing for thyroid hormone assessment","volume":"23","author":"Stan","year":"2013","journal-title":"Thyroid"},{"issue":"20","key":"10.1016\/j.ecl.2021.12.004_bib36","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1056\/NEJM198911163212001","article-title":"Use of corticosteroids to prevent progression of Graves' ophthalmopathy after radioiodine therapy for hyperthyroidism","volume":"321","author":"Bartalena","year":"1989","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.ecl.2021.12.004_bib37","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1002\/ijc.2910500611","article-title":"Cancer mortality after iodine-131 therapy for hyperthyroidism","volume":"50","author":"Hall","year":"1992","journal-title":"Int J Cancer"},{"issue":"10","key":"10.1016\/j.ecl.2021.12.004_bib38","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1002\/cncr.22635","article-title":"Increased cancer incidence after radioiodine treatment for hyperthyroidism","volume":"109","author":"Metso","year":"2007","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.ecl.2021.12.004_bib39","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1001\/jamainternmed.2019.0981","article-title":"Association of radioactive iodine treatment with cancer mortality in patients with hyperthyroidism","volume":"179","author":"Kitahara","year":"2019","journal-title":"JAMA Intern Med"},{"issue":"5","key":"10.1016\/j.ecl.2021.12.004_bib40","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1093\/oxfordjournals.aje.a114900","article-title":"Radioactive iodine therapy and breast cancer. A follow-up study of hyperthyroid women","volume":"127","author":"Goldman","year":"1988","journal-title":"Am J Epidemiol"},{"issue":"9170","key":"10.1016\/j.ecl.2021.12.004_bib41","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1016\/S0140-6736(98)12295-X","article-title":"Cancer incidence and mortality after radioiodine treatment for hyperthyroidism: a population-based cohort study","volume":"353","author":"Franklyn","year":"1999","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.ecl.2021.12.004_bib42","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1001\/jama.280.4.347","article-title":"Cancer mortality following treatment for adult hyperthyroidism. Cooperative Thyrotoxicosis Therapy Follow-up Study Group","volume":"280","author":"Ron","year":"1998","journal-title":"Jama"},{"issue":"11","key":"10.1016\/j.ecl.2021.12.004_bib43","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.2967\/jnumed.119.235929","article-title":"There is no association of radioactive iodine treatment with cancer mortality in patients with hyperthyroidism","volume":"60","author":"Greenspan","year":"2019","journal-title":"J\u00a0Nucl Med"},{"issue":"7","key":"10.1016\/j.ecl.2021.12.004_bib44","doi-asserted-by":"crossref","first-page":"e209660","DOI":"10.1001\/jamanetworkopen.2020.9660","article-title":"Association of radioactive iodine, antithyroid drug, and surgical treatments with solid cancer mortality in patients with hyperthyroidism","volume":"3","author":"Kitahara","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"4","key":"10.1016\/j.ecl.2021.12.004_bib45","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1245\/s10434-014-4095-6","article-title":"Clinical and socioeconomic factors influence treatment decisions in Graves' disease","volume":"22","author":"Elfenbein","year":"2015","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"10.1016\/j.ecl.2021.12.004_bib46","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1097\/SLA.0b013e31812eecc4","article-title":"Racial disparities in clinical and economic outcomes from thyroidectomy","volume":"246","author":"Sosa","year":"2007","journal-title":"Ann Surg"},{"issue":"2","key":"10.1016\/j.ecl.2021.12.004_bib47","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S0889-8529(03)00010-0","article-title":"Perioperative management of the thyrotoxic patient","volume":"32","author":"Langley","year":"2003","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"5","key":"10.1016\/j.ecl.2021.12.004_bib48","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1111\/j.1365-2265.1991.tb03562.x","article-title":"Rapid preoperative preparation in hyperthyroidism","volume":"35","author":"Baeza","year":"1991","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.ecl.2021.12.004_bib49","doi-asserted-by":"crossref","first-page":"w14243","DOI":"10.4414\/smw.2016.14243","article-title":"Rapid preoperative blockage of thyroid hormone production\/secretion in patients with Graves' disease","volume":"146","author":"Fischli","year":"2016","journal-title":"Swiss Med Wkly"},{"issue":"16","key":"10.1016\/j.ecl.2021.12.004_bib50","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1056\/NEJMra1510030","article-title":"Graves' Disease","volume":"375","author":"Smith","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.ecl.2021.12.004_bib51","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1210\/er.2018-00066","article-title":"Insulin-like growth factor-i receptor and thyroid-associated ophthalmopathy","volume":"40","author":"Smith","year":"2019","journal-title":"Endocr Rev"},{"issue":"1","key":"10.1016\/j.ecl.2021.12.004_bib52","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1046\/j.1365-2265.1997.2331047.x","article-title":"Clinical activity score as a guide in the management of patients with Graves' ophthalmopathy","volume":"47","author":"Mourits","year":"1997","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.ecl.2021.12.004_bib53","first-page":"249125","article-title":"Graves' Ophthalmopathy: VISA versus EUGOGO Classification, Assessment, and Management","volume":"2015","author":"Barrio-Barrio","year":"2015","journal-title":"J\u00a0Ophthalmol"},{"key":"10.1016\/j.ecl.2021.12.004_bib54","first-page":"477","article-title":"The epidemiologic characteristics and clinical course of ophthalmopathy associated with autoimmune thyroid disease in Olmsted County, Minnesota","volume":"92","author":"Bartley","year":"1994","journal-title":"Trans Am Ophthalmol Soc"},{"issue":"7","key":"10.1016\/j.ecl.2021.12.004_bib55","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1210\/jc.2012-1275","article-title":"Incidence and clinical presentation of moderate to severe graves' orbitopathy in a Danish population before and after iodine fortification of salt","volume":"97","author":"Laurberg","year":"2012","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.ecl.2021.12.004_bib56","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/j.1365-2265.1995.tb02597.x","article-title":"Natural history of thyroid associated ophthalmopathy","volume":"42","author":"Perros","year":"1995","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"4","key":"10.1016\/j.ecl.2021.12.004_bib57","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1210\/jc.2012-3873","article-title":"Prevalence and natural history of Graves' orbitopathy in a large series of patients with newly diagnosed graves' hyperthyroidism seen at a single center","volume":"98","author":"Tanda","year":"2013","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.ecl.2021.12.004_bib58","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3389\/fendo.2016.00021","article-title":"Dissecting the Genetic Susceptibility to Graves' Disease in a Cohort of Patients of Italian Origin","volume":"7","author":"Lombardi","year":"2016","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"5","key":"10.1016\/j.ecl.2021.12.004_bib59","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1210\/clinem\/dgab070","article-title":"Statins decrease the risk of orbitopathy in newly diagnosed patients with Graves Disease","volume":"106","author":"Nilsson","year":"2021","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.ecl.2021.12.004_bib60","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.beem.2011.11.009","article-title":"Neuroimaging of Graves' orbitopathy","volume":"26","author":"M\u00fcller-Forell","year":"2012","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"11","key":"10.1016\/j.ecl.2021.12.004_bib61","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.6061\/clinics\/2012(11)18","article-title":"Imaging studies for diagnosing Graves' orbitopathy and dysthyroid optic neuropathy","volume":"67","author":"Gon\u00e7alves","year":"2012","journal-title":"Clinics (Sao Paulo)"},{"issue":"2","key":"10.1016\/j.ecl.2021.12.004_bib62","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1159\/000444482","article-title":"2015 Italian Survey of Clinical Practice Patterns in the Management of Graves' Disease: Comparison with European and North American Surveys","volume":"5","author":"Negro","year":"2016","journal-title":"Eur Thyroid J"},{"issue":"7","key":"10.1016\/j.ecl.2021.12.004_bib63","doi-asserted-by":"crossref","first-page":"2711","DOI":"10.1210\/jc.2015-4294","article-title":"Risk Factors for Graves' Orbitopathy; the Australian Thyroid-Associated Orbitopathy Research (ATOR) Study","volume":"101","author":"Khong","year":"2016","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.ecl.2021.12.004_bib64","first-page":"218","article-title":"Prevention of thyroid associated-ophthalmopathy in children and adults: current views and management of preventable risk factors","volume":"4","author":"Krassas","year":"2007","journal-title":"Pediatr Endocrinol Rev"},{"issue":"20","key":"10.1016\/j.ecl.2021.12.004_bib65","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1056\/NEJMoa1012985","article-title":"Selenium and the course of mild Graves' orbitopathy","volume":"364","author":"Marcocci","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.ecl.2021.12.004_bib66","doi-asserted-by":"crossref","first-page":"5234","DOI":"10.1210\/jc.2005-0148","article-title":"Randomized, single blind trial of intravenous versus oral steroid monotherapy in Graves' orbitopathy","volume":"90","author":"Kahaly","year":"2005","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"12","key":"10.1016\/j.ecl.2021.12.004_bib67","doi-asserted-by":"crossref","first-page":"4454","DOI":"10.1210\/jc.2012-2389","article-title":"Efficacy and safety of three different cumulative doses of intravenous methylprednisolone for moderate to severe and active Graves' orbitopathy","volume":"97","author":"Bartalena","year":"2012","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.ecl.2021.12.004_bib68","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1089\/thy.2000.10.521","article-title":"Fatal liver failure after high-dose glucocorticoid pulse therapy in a patient with severe thyroid eye disease","volume":"10","author":"Weissel","year":"2000","journal-title":"Thyroid"},{"issue":"2","key":"10.1016\/j.ecl.2021.12.004_bib69","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1530\/EJE-11-0779","article-title":"Fatal and non-fatal adverse events of glucocorticoid therapy for Graves' orbitopathy: a questionnaire survey among members of the European Thyroid Association","volume":"166","author":"Marcocci","year":"2012","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"10.1016\/j.ecl.2021.12.004_bib70","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1056\/NEJMoa1910434","article-title":"Teprotumumab for the Treatment of Active Thyroid Eye Disease","volume":"382","author":"Douglas","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"18","key":"10.1016\/j.ecl.2021.12.004_bib71","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1056\/NEJMoa1614949","article-title":"Teprotumumab for Thyroid-Associated Ophthalmopathy","volume":"376","author":"Smith","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.ecl.2021.12.004_bib72","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2021-242153","article-title":"Rapidly progressive cognitive decline associated with teprotumumab in thyroid eye disease","volume":"14","author":"Hoang","year":"2021","journal-title":"BMJ Case Rep"},{"issue":"1","key":"10.1016\/j.ecl.2021.12.004_bib73","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s42000-019-00133-5","article-title":"Challenges and perspectives of selenium supplementation in Graves' disease and orbitopathy","volume":"19","author":"Bednarczuk","year":"2020","journal-title":"Hormones (Athens)"},{"issue":"4","key":"10.1016\/j.ecl.2021.12.004_bib74","doi-asserted-by":"crossref","first-page":"G43","DOI":"10.1530\/EJE-21-0479","article-title":"The 2021 European Group on Graves' orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves' orbitopathy","volume":"185","author":"Bartalena","year":"2021","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"10.1016\/j.ecl.2021.12.004_bib75","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1007\/s40618-016-0441-9","article-title":"Prospective, systematically recorded mycophenolate safety data in Graves' orbitopathy","volume":"39","author":"Riedl","year":"2016","journal-title":"J\u00a0Endocrinol Invest"},{"issue":"7","key":"10.1016\/j.ecl.2021.12.004_bib76","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1358\/dot.2009.45.7.1384878","article-title":"Mycophenolate mofetil: an update","volume":"45","author":"Villarroel","year":"2009","journal-title":"Drugs Today (Barc)"},{"issue":"2","key":"10.1016\/j.ecl.2021.12.004_bib77","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/cen.13170","article-title":"Efficacy and safety of mycophenolate mofetil in patients with active moderate-to-severe Graves' orbitopathy","volume":"86","author":"Ye","year":"2017","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"4","key":"10.1016\/j.ecl.2021.12.004_bib78","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/S2213-8587(18)30020-2","article-title":"Mycophenolate plus methylprednisolone versus methylprednisolone alone in active, moderate-to-severe Graves' orbitopathy (MINGO): a randomised, observer-masked, multicentre trial","volume":"6","author":"Kahaly","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"10.1016\/j.ecl.2021.12.004_bib79","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1007\/s40618-019-01161-z","article-title":"Systemic safety analysis of mycophenolate in Graves' orbitopathy","volume":"43","author":"Lee","year":"2020","journal-title":"J\u00a0Endocrinol Invest"},{"key":"10.1016\/j.ecl.2021.12.004_bib80","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ajo.2018.07.038","article-title":"Efficacy of tocilizumab in patients with moderate-to-severe corticosteroid-resistant graves orbitopathy: a randomized clinical trial","volume":"195","author":"Perez-Moreiras","year":"2018","journal-title":"Am J Ophthalmol"},{"issue":"3","key":"10.1016\/j.ecl.2021.12.004_bib81","doi-asserted-by":"crossref","first-page":"e64","DOI":"10.1097\/IOP.0000000000001346","article-title":"Subcutaneous tocilizumab for thyroid Eye Disease: Simplified Dosing and Delivery","volume":"35","author":"Copperman","year":"2019","journal-title":"Ophthalmic Plast Reconstr Surg"},{"issue":"1","key":"10.1016\/j.ecl.2021.12.004_bib82","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jcjo.2020.07.020","article-title":"Treatment of corticosteroid-resistant thyroid eye disease with subcutaneous tocilizumab","volume":"56","author":"Silkiss","year":"2021","journal-title":"Can J Ophthalmol"},{"issue":"2","key":"10.1016\/j.ecl.2021.12.004_bib83","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.clim.2008.12.005","article-title":"Rituximab treatment in a patient with severe thyroid-associated ophthalmopathy: effects on orbital lymphocytic infiltrates","volume":"131","author":"Salvi","year":"2009","journal-title":"Clin Immunol"},{"issue":"2","key":"10.1016\/j.ecl.2021.12.004_bib84","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1210\/jc.2014-3014","article-title":"Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves' orbitopathy: a randomized controlled study","volume":"100","author":"Salvi","year":"2015","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.ecl.2021.12.004_bib85","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1210\/jc.2014-2572","article-title":"Randomized controlled trial of rituximab in patients with Graves' orbitopathy","volume":"100","author":"Stan","year":"2015","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.ecl.2021.12.004_bib86","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s42000-021-00282-6","article-title":"Intravenous rituximab therapy for active Graves' ophthalmopathy: a meta-analysis","volume":"20","author":"Chen","year":"2021","journal-title":"Hormones (Athens)"},{"issue":"5","key":"10.1016\/j.ecl.2021.12.004_bib87","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1002\/phar.2111","article-title":"Efficacy and safety of rituximab for the treatment of Graves' Orbitopathy: a meta-analysis of randomized controlled trials","volume":"38","author":"Shen","year":"2018","journal-title":"Pharmacotherapy"},{"issue":"1","key":"10.1016\/j.ecl.2021.12.004_bib88","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s12886-018-0679-4","article-title":"Does rituximab improve clinical outcomes of patients with thyroid-associated ophthalmopathy? A systematic review and meta-analysis","volume":"18","author":"Wang","year":"2018","journal-title":"BMC Ophthalmol"},{"issue":"3","key":"10.1016\/j.ecl.2021.12.004_bib89","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1038\/eye.2017.260","article-title":"Orbital decompression for thyroid eye disease: methods, outcomes, and complications","volume":"32","author":"Jefferis","year":"2018","journal-title":"Eye (Lond)"},{"issue":"3","key":"10.1016\/j.ecl.2021.12.004_bib90","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1001\/archopht.118.3.410","article-title":"A\u00a0simple maneuver to reposit a subluxed globe","volume":"118","author":"Tse","year":"2000","journal-title":"Arch Ophthalmol"},{"issue":"12","key":"10.1016\/j.ecl.2021.12.004_bib91","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1001\/archopht.122.12.1882","article-title":"Normalization of upper eyelid height and contour after bony decompression in thyroid-related ophthalmopathy: a digital image analysis","volume":"122","author":"Chang","year":"2004","journal-title":"Arch Ophthalmol"}],"container-title":["Endocrinology and Metabolism Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889852921001274?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889852921001274?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:48:08Z","timestamp":1760176088000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889852921001274"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":91,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["S0889852921001274"],"URL":"https:\/\/doi.org\/10.1016\/j.ecl.2021.12.004","relation":{},"ISSN":["0889-8529"],"issn-type":[{"value":"0889-8529","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"2022\u00a0Update on Clinical Management of Graves Disease and Thyroid Eye Disease","name":"articletitle","label":"Article Title"},{"value":"Endocrinology and Metabolism Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ecl.2021.12.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}